Now #ESMO26: In a phase 2 trial evaluating an off-the-shelf peptide vaccine in patients with mKRAS PDAC, the 1ry endpoint of DFS was not met but prespecified analyses showed that s

Nature Medicine· @NatureMedicine · X·2026-10-23 19:06· 2 天前评分90

正文 · 原文

Now #ESMO26: In a phase 2 trial evaluating an off-the-shelf peptide vaccine in patients with mKRAS PDAC, the 1ry endpoint of DFS was not met but prespecified analyses showed that significant DFS was seen in the vaccine arm in patients with ctDNA- disease. dlvr.it/TW27M9

3150 浏览 · 9 赞 · 5 转发 · 0 回复

会议摘要

1017P按 Developmental therapeutics 对上

Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors

https://esmocongress.esmo.org

NCT06110663NCT06110663按 - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy 对上

- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

https://esmocongress.esmo.org

来源：Nature Medicine · x.com